Danaher Corporation $DHR Position Increased by Godsey & Gibb Inc.

Posted by Stanley Muller on Oct 15th, 2026

Godsey & Gibb Inc. lifted its position in Danaher Corporation (NYSE:DHR – Free Report) by 218.4% in the third quarter, HoldingsChannel.com reports. The firm owned 4,457 shares of the conglomerate’s stock after acquiring an additional 3,057 shares during the period. Godsey & Gibb Inc.’s holdings in Danaher were worth $987,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marquette Asset Management LLC increased its holdings in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the period. N.E.W. Advisory Services LLC bought a new position in shares of Danaher during the 2nd quarter worth about $25,000. Main Street Group LTD bought a new position in shares of Danaher during the 1st quarter worth about $25,000. Field & Main Bank acquired a new stake in shares of Danaher during the 2nd quarter valued at about $29,000. Finally, Evolution Wealth Management Inc. boosted its position in shares of Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Barclays increased their price target on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Guggenheim lifted their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Wells Fargo & Company lowered their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Royal Bank Of Canada increased their target price on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Finally, UBS Group began coverage on shares of Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $235.41.

Get Our Latest Report on DHR

Danaher Stock Up 0.8%

Shares of DHR opened at $224.65 on Thursday. The company has a market capitalization of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The business’s 50 day simple moving average is $212.92 and its 200-day simple moving average is $195.39.

Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the company posted $0.77 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Danaher Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.